“The science is moving very, very fast”: The experimental GLP-3 weight-loss drug retatrutide just set a new milestone for these medications. Here’s what to know.
Post
Conversation
Post your reply
Small correction: there's no "GLP-3." Retatrutide hits three different receptors: GLP-1 (what semaglutide targets), GIP (what tirzepatide added) and glucagon (the new one). The glucagon part raises energy burn instead of only cutting appetite, which is likely why the number
GLP-2 is teduglutide (Gattex) and no GLP3 drug exist. Do better "Scientific" America 🤣
$70M in revenue, >1M daily active users.
CHAI is hiring engineers in Palo Alto. We offer 1.5x in comp. We pay 100% cash salary - hires buy as many stock-options as they like.
SDE2's takehome $500k/yr.
SDE3 $750k/yr.
Principal SDE $1M/yr ++